ArticleJournal of multidisciplinary healthcare2026
Comparative Analysis of the Average Recommendation Time for the Incorporation of Biological Drugs for Cancer and Rheumatoid Arthritis.
Article in Journal of multidisciplinary healthcare, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare the average time between the registration of a biological drug and its recommendation for incorporation for rheumatoid arthritis (RA) and cancer (CA) at national and international levels. Methods: This retrospective, comparative study analyzed the time taken to incorporate biological drugs recommended by National Commission for the Incorporation of Technologies (CONITEC) in the Brazilian Unified Health System(SUS) for RA and CA from January 1, 2012, to March 28, 2024. The incorporation time in Brazil was compared to that of regulatory bodies in England and Australia for the same treatments. Kaplan-Meier curves and the Log rank test were used to estimate time differences between countries. Results: In Brazil, biological drugs for RA took an average of 2,019 days from the National Health Surveillance Agency (ANVISA) approval to CONITEC's incorporation recommendation. In England, the averages were 1,242 days for RA and 1,683 for CA, while in Australia, it was 744 days for RA and 1,315 for CA. Australia incorporated drugs faster than both England and Brazil. Conclusion: The lengthy process in Brazil for incorporating biological technologies for RA and CA may hinder access, delaying treatment for many patients. This barrier is particularly significant for low-income individuals who rely exclusively on the SUS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.